Prevention of poststroke depression with milnacipran in patients with acute ischemic stroke

A double-blind randomized placebo-controlled trial

Ching Shu Tsai, Chen-Long Wu, Shih Yong Chou, Hin Yeung Tsang, Tai Hsin Hung, Jian An Su

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Poststroke depression (PSD) is one of the most frequent neuropsychiatric consequences of stroke. It has been shown to be associated with both impaired recovery and increased mortality. The purpose of this study is to investigate the prophylactic effect of milnacipran in PSD. Ninety-two patients were enrolled in the 12 months of this double-blind randomized placebo-controlled trial. The assessment was performed at baseline, and at the first, third, sixth, ninth and 12th month after enrollment. The definition of PSD was in accordance with the diagnostic criteria of major depressive episode based on the Diagnostic and Statistical Manual, fourth edition. Forty-six patients were randomized to the treatment group with milnacipran and another 46 patients to the placebo group. No significant differences were found between the two groups in terms of sex (P=0.83), age (P=0.08), marital status (P=0.66), occupation (P=0.22), educational level (P=0.29), and drug side-effects (P=0.73). The incidence of depression in the two groups was 2.22% and 15.22%, respectively. Milnacipran was proved to have a statistically significant advantage in preventing PSD (P<0.05). In conclusion, milnacipran could prevent the development of depression in the first year following a stroke and is safe to use without significant adverse effects in stroke patients.

Original languageEnglish
Pages (from-to)263-267
Number of pages5
JournalInternational Clinical Psychopharmacology
Volume26
Issue number5
DOIs
Publication statusPublished - 2011 Sep 1

Fingerprint

Randomized Controlled Trials
Stroke
Placebos
Depression
Marital Status
Drug-Related Side Effects and Adverse Reactions
Occupations
milnacipran
Mortality
Incidence
Therapeutics

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

@article{15566973533f4af79a44b5588f60996a,
title = "Prevention of poststroke depression with milnacipran in patients with acute ischemic stroke: A double-blind randomized placebo-controlled trial",
abstract = "Poststroke depression (PSD) is one of the most frequent neuropsychiatric consequences of stroke. It has been shown to be associated with both impaired recovery and increased mortality. The purpose of this study is to investigate the prophylactic effect of milnacipran in PSD. Ninety-two patients were enrolled in the 12 months of this double-blind randomized placebo-controlled trial. The assessment was performed at baseline, and at the first, third, sixth, ninth and 12th month after enrollment. The definition of PSD was in accordance with the diagnostic criteria of major depressive episode based on the Diagnostic and Statistical Manual, fourth edition. Forty-six patients were randomized to the treatment group with milnacipran and another 46 patients to the placebo group. No significant differences were found between the two groups in terms of sex (P=0.83), age (P=0.08), marital status (P=0.66), occupation (P=0.22), educational level (P=0.29), and drug side-effects (P=0.73). The incidence of depression in the two groups was 2.22{\%} and 15.22{\%}, respectively. Milnacipran was proved to have a statistically significant advantage in preventing PSD (P<0.05). In conclusion, milnacipran could prevent the development of depression in the first year following a stroke and is safe to use without significant adverse effects in stroke patients.",
author = "Tsai, {Ching Shu} and Chen-Long Wu and Chou, {Shih Yong} and Tsang, {Hin Yeung} and Hung, {Tai Hsin} and Su, {Jian An}",
year = "2011",
month = "9",
day = "1",
doi = "10.1097/YIC.0b013e32834a5c64",
language = "English",
volume = "26",
pages = "263--267",
journal = "International Clinical Psychopharmacology",
issn = "0268-1315",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

Prevention of poststroke depression with milnacipran in patients with acute ischemic stroke : A double-blind randomized placebo-controlled trial. / Tsai, Ching Shu; Wu, Chen-Long; Chou, Shih Yong; Tsang, Hin Yeung; Hung, Tai Hsin; Su, Jian An.

In: International Clinical Psychopharmacology, Vol. 26, No. 5, 01.09.2011, p. 263-267.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prevention of poststroke depression with milnacipran in patients with acute ischemic stroke

T2 - A double-blind randomized placebo-controlled trial

AU - Tsai, Ching Shu

AU - Wu, Chen-Long

AU - Chou, Shih Yong

AU - Tsang, Hin Yeung

AU - Hung, Tai Hsin

AU - Su, Jian An

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Poststroke depression (PSD) is one of the most frequent neuropsychiatric consequences of stroke. It has been shown to be associated with both impaired recovery and increased mortality. The purpose of this study is to investigate the prophylactic effect of milnacipran in PSD. Ninety-two patients were enrolled in the 12 months of this double-blind randomized placebo-controlled trial. The assessment was performed at baseline, and at the first, third, sixth, ninth and 12th month after enrollment. The definition of PSD was in accordance with the diagnostic criteria of major depressive episode based on the Diagnostic and Statistical Manual, fourth edition. Forty-six patients were randomized to the treatment group with milnacipran and another 46 patients to the placebo group. No significant differences were found between the two groups in terms of sex (P=0.83), age (P=0.08), marital status (P=0.66), occupation (P=0.22), educational level (P=0.29), and drug side-effects (P=0.73). The incidence of depression in the two groups was 2.22% and 15.22%, respectively. Milnacipran was proved to have a statistically significant advantage in preventing PSD (P<0.05). In conclusion, milnacipran could prevent the development of depression in the first year following a stroke and is safe to use without significant adverse effects in stroke patients.

AB - Poststroke depression (PSD) is one of the most frequent neuropsychiatric consequences of stroke. It has been shown to be associated with both impaired recovery and increased mortality. The purpose of this study is to investigate the prophylactic effect of milnacipran in PSD. Ninety-two patients were enrolled in the 12 months of this double-blind randomized placebo-controlled trial. The assessment was performed at baseline, and at the first, third, sixth, ninth and 12th month after enrollment. The definition of PSD was in accordance with the diagnostic criteria of major depressive episode based on the Diagnostic and Statistical Manual, fourth edition. Forty-six patients were randomized to the treatment group with milnacipran and another 46 patients to the placebo group. No significant differences were found between the two groups in terms of sex (P=0.83), age (P=0.08), marital status (P=0.66), occupation (P=0.22), educational level (P=0.29), and drug side-effects (P=0.73). The incidence of depression in the two groups was 2.22% and 15.22%, respectively. Milnacipran was proved to have a statistically significant advantage in preventing PSD (P<0.05). In conclusion, milnacipran could prevent the development of depression in the first year following a stroke and is safe to use without significant adverse effects in stroke patients.

UR - http://www.scopus.com/inward/record.url?scp=80051786635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051786635&partnerID=8YFLogxK

U2 - 10.1097/YIC.0b013e32834a5c64

DO - 10.1097/YIC.0b013e32834a5c64

M3 - Article

VL - 26

SP - 263

EP - 267

JO - International Clinical Psychopharmacology

JF - International Clinical Psychopharmacology

SN - 0268-1315

IS - 5

ER -